<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18423">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02045810</url>
  </required_header>
  <id_info>
    <org_study_id>JH2013-2</org_study_id>
    <secondary_id>2013-003607-19</secondary_id>
    <nct_id>NCT02045810</nct_id>
  </id_info>
  <brief_title>Surgical Pleth Index- Relevance in Small Children</brief_title>
  <acronym>SPIinChildren</acronym>
  <official_title>Surgical Pleth Index - Relevance in Small Children. A Randomised Double Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <authority>Finland: Finnish Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgical Pleth index is a novel device aimed for measurement of intraoperative nosiseption.
      It has not been tested on small children. The aim of this study is to measure, whether there
      is a difference in nosiception measured by SPI in a group receiving local anesthetics prior
      to operation compared to group receiving plasebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>SPI at the time of start of surgery</measure>
    <time_frame>the start of surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Measurement of Nosiseption Durin Anesthesia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in group receive Ileoinguinal block before the start of surgery, and an injection of plasebo saline after surgery. Injectate is blinded from caregiver.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive a plasebo saline injetion at the site of ileoinguinal block prior to surgery and an injectio with local anesthetics after surgery. The treatment group is blinded for caregiver.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        age 0-2 years Elective surgery planned for inguinal hernia, or testicle retention Written
        informed consent from parent received ASA I-III

        Exclusion Criteria:

          -  Exstrasystolias, known cardiac problem, medication affecting rhytm, allergy to drugs
             used
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jarkko Harju, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arvi Yli-Hankala, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jarkko Harju</last_name>
    <phone>00358331165368</phone>
    <email>jarkko.harju@fimnet.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarkko Harju, MD</last_name>
      <phone>00358331165368</phone>
      <email>jarkko.harju@fimnet.fi</email>
    </contact>
    <investigator>
      <last_name>Jarkko Harju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
